WATCHMAN FLX versus NOAC for EMbolic ProtectION in the Management of Patients with Non-Valvular Atrial Fibrillation
Champion Atrial Fibrillation (AF)
Sponsor: Boston Scientific Corporation
Enrolling: Male and Female Patients
Clinic Visits: 9
IRB Number: AAAT2212
U.S. Govt. ID: NCT04394546
Contact: Kate Dalton: 347-514-3366 / keb2114@cumc.columbia.edu
Additional Study Information: This is a prospective, randomized, multi-center global investigational study. The primary objective is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants (NOACs - drugs that inhibits clotting) in patients with Atrial Fibrillation (AF) - irregular heart rhythm caused by other things, such as high blood pressure or an overactive thyroid gland.
This study is closed
Investigator
Robert Sommer, MD
Do You Qualify?
Do you have atrial fibrillation (AF)? Yes No
Are you on anticoagulation for reasons other than AF-related stroke risk reduction? Yes No
Have you had a transient ischemic attack (TIA) or Stroke? Yes No
Have you had a patent foramen ovale (PFO)/ atrial septal defect (ASD) closed? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Kate Dalton
keb2114@cumc.columbia.edu
347-514-3366
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE